Pipeline and licensing upside offsets generic-drug pressure, supporting an unchanged Market-Perform view on CSPC

Overview

This model update argues that CSPC's late-stage innovative pipeline and improving out-licensing execution are increasingly important long-term growth drivers, even as mature products, generic-drug erosion and lower TG103 expectations constrain the nearer-term outlook. Bernstein retains Market-Perform and a HK$10.7 target price.

Core views

Bernstein is incrementally more positive after reassessing CSPC's pipeline, but sees near-term earnings constrained by a mature marketed portfolio and continued generic-drug erosion. Its revised model expects revenue to rise from CNY26bn in 2025 to CNY57bn in 2033, with innovative products launched after 2026 supplying most incremental growth. Marketed innovative-drug revenue is expected to remain broadly stable: growth from newer products such as Mingfule is expected to offset the gradual decline of mature blockbusters including NBP. The revised long-term outlook also incorporates a lower core EBIT-margin assumption of 28%, down from 30%, based on 2025 results. SYS6010, CSPC's EGFR ADC, is the report's principal pipeline value driver. In second-line-plus EGFR-mutant NSCLC, its objective response rates were 45.7% after EGFR-TKI failure and 34.7% after EGFR-TKI plus platinum-based chemotherapy failure, at the lower end of the 45%-60% range for leading peers. However, Bernstein considers the survival data more encouraging: in the EGFR-TKI-plus-chemotherapy-failed population, median PFS was 7.6 months and median OS was 19.4 months, broadly comparable with sac-TMT and numerically ahead of most evaluated regimens. The firm therefore sees this setting as the most credible commercial opportunity. In I/O-treated EGFR wild-type NSCLC, SYS6010 reported a 36% ORR and 5.3-month median PFS in nonsquamous patients, while OS remains immature. Conversely, first-line EGFR wild-type NSCLC remains a less convincing opportunity because reported 51%-53% response rates lag several competing combinations and there is not yet evidence of superior PFS or OS. CSPC has initiated eight Phase III trials and one Phase II/III trial for SYS6010; the key catalyst is SYNSTAR-01 in second-line-plus EGFR-TKI-failed EGFR-mutant NSCLC, expected in 2H26 at ESMO Asia. Bernstein raises risk-adjusted China peak sales for SYS6010 to CNY6.1bn from CNY5.1bn, contingent on pivotal-study success. Other oncology assets provide both breadth and uneven evidence. JMT101 appears less differentiated in NSCLC, where cross-trial comparisons show its first-line EGFR-mutant combination trailing leading third-generation EGFR combinations and its exon20ins regimen showing stronger confirmed ORR but weaker median PFS and OS than several peers. Bernstein instead sees more promise in late-line colorectal cancer, where JMT101's ORR and median PFS numerically exceeded regorafenib in RAS/BRAF wild-type, non-MSI-H/dMMR disease. It lowers assumed NSCLC share and raises CRC share, producing an approximately CNY900mn reduction in peak-sales estimates. SYS6043, CSPC's B7-H3 ADC, reported ORR of 64%-75% in second-line-plus SCLC, versus 71% for Kelun's SKB500 and approximately twice the standard-of-care rate for lurbinectedin; nevertheless, survival data are immature in a crowded market. In metabolics, Bernstein cuts TG103 peak sales to CNY2bn from CNY5bn. The asset achieved 5.4% placebo-adjusted weight reduction at Week 12, placing it at the low end of subcutaneous GLP-1 peers whose leading results were generally double-digit. The firm judges this efficacy insufficiently differentiated in an obesity market facing more innovative candidates and growing biosimilar competition. It remains constructive on CSPC's wider cardiometabolic pipeline across obesity, dyslipidemia, hypertension and nephropathy, spanning peptides, siRNA and monoclonal antibodies, but notes that—apart from efmedaglutide alfa—most programs lack disclosed efficacy data. Future clinical readouts are therefore necessary before the firm assigns more material upside. Bernstein also views CSPC's mRNA platform as strategically valuable but distinct from the individualized neoantigen-vaccine theme attracting investor attention. CSPC's portfolio focuses on prophylactic vaccines and off-the-shelf therapeutic mRNA programs rather than patient-specific neoantigen therapies. The company is therefore not viewed as a direct beneficiary of near-term enthusiasm for individualized cancer vaccines, although its integrated mRNA and lipid-nanoparticle manufacturing capabilities provide long-term optionality. Separately, CSPC has added 30 previously unprojected pipeline programs, including seven preclinical and 15 Phase II assets; Bernstein updates projected revenue from these unprojected assets to CNY10.5bn in 2033E. Generic-drug revenue remains a material drag. Direct exposure to VBP Batch 12 is limited, with no included product contributing more than 5% of CSPC revenue, but prior batches have already caused significant 2025 sales declines for products including Duomeisu, Jinyouli, Shuanling and Abikang. As VBP pressure typically persists for two to three years after inclusion, Bernstein forecasts Gx revenue declines of 10% in 2026 and 7% in 2027 and expects it to account for less than 10% of total product revenue by 2033. Its 2032E Gx revenue estimate is cut 56% to reflect VBP Batches 10-12. Business development is a major offset. CSPC completed five out-licensing deals in 2025 with aggregate disclosed value of about US$10bn and upfront payments of about US$260mn, followed by two transactions in 2026, taking disclosed deal value to about US$20bn. Existing signed deals are expected to support CNY4bn-CNY5bn or more of annual licensing income by 2030E. Bernstein raises its 2033E licensing-income forecast from CNY4.3bn to CNY7bn and its 2032E BD-income estimate by about 60% to CNY6.4bn. The forecast assumes SYS6010 is partnered in 2027E in a deal with an estimated total value of about US$5bn and that CSPC files one BD deal annually from 2027 onward. The unchanged target price reflects a blended, equally weighted valuation. The DCF produces a one-year-forward value of CNY10.9 per share using an 11.0% WACC, 2.0% terminal-growth rate and explicit forecasts through 2039; the P/E method produces CNY9.2 using a 14x one-year-forward multiple, lowered from 18.4x; and EV/EBITDA produces CNY9.9 using an 11x multiple, lowered from 12x. The blended result is CNY10.0 per share, equivalent to HK$10.7. Higher SYS6010, pipeline and licensing assumptions are thus offset by lower TG103 and Gx forecasts, reduced valuation multiples and a lower margin outlook, leading Bernstein to retain Market-Perform.

Analysis framework

Bernstein updates a segment-level revenue and earnings model, reassesses pipeline assets through cross-trial efficacy and competitive comparisons, estimates risk-adjusted peak sales by indication, and incorporates licensing assumptions based on completed and expected deals. It then blends equally weighted DCF, one-year-forward P/E and EV/EBITDA valuations to derive the target price.

Methodology notes

• Industry AnalysisSupply-demand framework

  Pipeline and competitive-positioning assessment

  The report compares clinical efficacy, treatment settings, competitors and expected adoption to revise commercial assumptions for individual drug candidates.

• Valuation methodsDCF (Discounted Cash Flow)

  Discounted cash flow valuation

  Bernstein projects CSPC through 2039 and discounts cash flows using an 11.0% WACC and 2.0% terminal growth rate.

• Valuation methodsP/E and PEG Valuation

  One-year-forward P/E valuation

  The report applies a 14x forward P/E multiple to estimated earnings, down from 18.4x previously.

• Valuation methodsEV/EBITDA valuation

  One-year-forward EV/EBITDA valuation

  The report applies an 11x forward EV/EBITDA multiple, down from 12x, alongside DCF and P/E in an equal-weight blend.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• CSPC Pharmaceutical Group Ltd (01093.HK)

  Primary covered company; pipeline and licensing growth are expected to offset mature-product and Gx pressure over time.

  Strengths

  Broader innovative pipeline, increased SYS6010 value estimate, integrated mRNA/LNP capabilities and stronger out-licensing execution.

  Weaknesses

  Near-term earnings constrained by mature products; TG103 has modest comparative efficacy; Gx revenue remains under VBP pressure.

  Comparison

  SYS6010 survival data are broadly comparable with sac-TMT in a key EGFR-mutant setting, while TG103 ranks at the lower end of GLP-1 efficacy comparisons.

  Risks

  VBP bid losses and delays in regulatory approval or commercialization of new molecules.

• SYS6010

  Key CSPC pipeline asset and principal projected oncology growth driver.

  Strengths

  Encouraging progression-control and survival data in EGFR-TKI-failed EGFR-mutant NSCLC; extensive pivotal-trial program.

  Weaknesses

  ORR trails several leading peers in EGFR-mutant NSCLC; first-line EGFR wild-type positioning is not yet differentiated.

  Comparison

  mOS of 19.4 months is broadly comparable with sac-TMT in the EGFR-TKI-plus-chemotherapy-failed population.

  Risks

  Pivotal studies may not succeed and assumed 2027 out-licensing may not materialize.

Key data

• Target priceHK$10.7 per shareUnchanged; equivalent to blended CNY10.0 one-year-forward value.
• Current priceHK$9.68Close price on 7 September 2026.
• Expected upside11%Versus the reported close price.
• Revenue forecastCNY26bn in 2025 to CNY57bn in 2033Growth is principally driven by innovative products launched after 2026.
• SYS6010 peak China salesCNY6.1bnRisk-adjusted estimate, raised from CNY5.1bn.
• SYS6010 efficacymPFS 7.6 months; mOS 19.4 monthsEGFR-TKI plus platinum-chemotherapy-failed EGFR-mutant NSCLC setting.
• TG103 peak salesCNY2bnReduced from CNY5bn after reassessing obesity-market competitiveness.
• 2033E licensing incomeCNY7bnRaised from CNY4.3bn.
• 2032E BD incomeCNY6.4bnAbout 60% above the prior CNY4.1bn estimate.
• Gx revenue change-10% in 2026; -7% in 2027Reflects lingering impact from prior VBP rounds.

Impact & implications

The report sees CSPC shifting from dependence on mature products toward innovative launches and licensing income. SYS6010 and broader pipeline optionality improve the long-term growth case, but the valuation remains balanced by clinical uncertainty, weaker TG103 prospects, persistent Gx erosion and lower valuation multiples.

Risks

• CSPC could lose more upcoming VBP bids for selected Gx molecules than Bernstein forecasts.
• Regulatory approval and commercialization of new molecules could be delayed.

What to watch

• Phase III SYNSTAR-01 readout for SYS6010 in 2H26, expected at ESMO Asia.
• Clinical validation from CSPC's broader cardiometabolic pipeline.
• Progress toward a potential SYS6010 out-licensing transaction assumed for 2027E.
• VBP outcomes and the resulting trajectory of Gx revenue.